Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan

Dialogues in Clinical Neuroscience

Volumn 14, Issue 3, 2012, Pages 263-279

  Doyle, Carolyn A ^a   McDougle, Christopher J ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Autism; Autism spectrum disorder; Autistic disorder; Pervasive developmental disorder; Treatment

Indexed keywords

ARIPIPRAZOLE; ATOMOXETINE; CITALOPRAM; CLOMIPRAMINE; CLONIDINE; CLOZAPINE; CYCLOSERINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GUANFACINE; HALOPERIDOL; MEMANTINE; METHYLPHENIDATE; MIRTAZAPINE; OLANZAPINE; PALIPERIDONE; PIMOZIDE; PLACEBO; QUETIAPINE; RISPERIDONE; SERTRALINE; TRAZODONE; VENLAFAXINE; ZIPRASIDONE;

AGGRESSION; AGITATION; AKATHISIA; ANOREXIA; ANXIETY; ARTICLE; ASPERGER SYNDROME; ATTENTION DEFICIT DISORDER; ATTENTION DISTURBANCE; AUTISM; AUTOMUTILATION; BEHAVIOR DISORDER; CATATONIA; COMPARATIVE STUDY; COMPULSION; CONSTIPATION; DECREASED APPETITE; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DISRUPTIVE BEHAVIOR; DIZZINESS; DROWSINESS; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; DRY SKIN; DYSKINESIA; DYSTONIA; DYSTONIC DISORDER; EAR DISEASE; ENERGY; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERACTIVITY; HYPERSALIVATION; HYPOMANIA; IMPULSIVENESS; INCREASED APPETITE; INSOMNIA; IRRITABILITY; LETHARGY; LIFESPAN; MEDICAL RECORD REVIEW; METABOLIC SYNDROME X; MOOD CHANGE; NAUSEA; NEUROTRANSMISSION; NOCTURNAL ENURESIS; OBSESSIVE COMPULSIVE DISORDER; OPEN STUDY; POLYURIA; PRIAPISM; PROSPECTIVE STUDY; PRURITUS; RASH; RHINITIS; RITUAL; SEDATION; SEIZURE; SEPARATION ANXIETY; SIDE EFFECT; SLEEP DISORDER; SOCIAL INTERACTION; SOMNOLENCE; STEREOTYPY; TACHYCARDIA; TREATMENT DURATION; TREATMENT REFUSAL; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BEHAVIORAL SYMPTOMS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; DEVELOPMENTAL DISABILITIES; HUMANS; INFANT; MEDLINE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 84875796899     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (142)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, Text Revision. Washington, DC: American Psychiatric Association; 2000.
2. Lecavalier L. Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification. J Autism Dev Disord. 2006;36:1101- 1114.
3. Gadow KD, Sverd J. Attention deficit hyperactivity disorder, chronic tic disorder, and methylphenidate. Adv Neurol 2006;99:197-207.
4. Goldstein S, Schwebach AJ. The comorbidity of pervasive developmental disorder and attention deficit hyperactivity disorder: results of a retrospective chart review. J Autism Dev Disord. 2004; 34: 329-339
5. Schain RJ, Freedman DX. Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. J Pediatr. 1961;58:315-320.
6. Ritvo ER, Yuwiler A, Geller E, Ornitz EM, Saeger K, Plotkin S. Increased blood serotonin and platelets in early infantile autism. Arch Gen Psychiatry. 1970;23:566-572.
7. Anderson GM, Freedman DX, Cohen DJ, et al. Whole blood serotonin in autistic and normal subjects. J Child Psychol Psychiatry. 1987;28:885-900.
8. Leboyer M, Philippe A, Bouvard M, et al. Whole blood serotonin and plasma beta-endorphin in autistic probands and their first-degree relatives. Biol Psychiatry. 1999;45:158-163.
9. McDougle CJ, Naylor ST, Cohen DJ, Aghajanian GK, Heninger GR, Price LH. Effects of tryptophan depletion in drug-free adults with autistic disorder. Arch Gen Psychiatry. 1996;53:993-1000.
10. Magen J. Negative results with clomipramine. J Am Acad Child Adolesc Psychiatry. 1993;32:1079-1080.
11. McDougle CJ, Price LH, Volkmar FR, et al. Clomipramine in autism: preliminary evidence of efficacy. J Am Acad Child Adolesc Psychiatry. 1992;31:746-750.
12. Brasic JR, Barnett JY, Kaplan D, et al. Clomipramine ameliorates adventitious movements and compulsions in prepubertal boys with autistic disorder and severe mental retardation. Neurology. 1994;44:1309-1312.
13. Sanchez LE, Campbell M, Small AM, Cueva JE, Armenteros JL, Adams PB. A pilot study of clomipramine in young autistic children. J Am Acad Child Adolesc Psychiatry. 1996;35:537-544.
14. Brasic JR, Barnett JY, Sheitman BB, Tsaltas MO. Adverse effects of clomipramine. J Am Acad Child Adolesc Psychiatry. 1997;36:1165-1166.
15. Brodkin ES, McDougle CJ, Naylor ST, Cohen DJ, Price LH. Clomipramine in adults with pervasive developmental disorders: a prospective open-label investigation. J Child Adolesc Psychopharmacol. 1997;7:109-121.
16. Gordon CT, Rapoport JL, Hamburger SD, State RC, Mannheim GB. Differential response of seven subjects with autistic disorder to clomipramine and desipramine. Am J Psychiatry. 1992;149:363-366
17. Gordon CT, State RC, Nelson JE, Hamburger SD, Rapoport JL. A doubleblind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry. 1993;50:441-447.
18. Remington G, Sloman L, Konstantareas M, Parker K, Gow R. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol. 2001;21:440-444.
19. Kauffmann C, Vance H, Pumariega AJ, Miller B. Fluvoxamine treatment of a child with severe PDD: a single case study. Psychiatry. 2001;64:268-277.
20. McDougle CJ, Kresch LE, Posey DJ. Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. J Autism Dev Disord. 2000;30:427-435.
21. Sugie Y, Sugie H, Fukuda T, et al. Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism. J Autism Dev Disord. 2005;35:377-385.
22. McDougle CJ, Price LH, Goodman WK. Fluvoxamine treatment of coincident autistic disorder and obsessive-compulsive disorder: a case report. J Autism Dev Disord. 1990;20:537-543.
23. Harvey RJ, Cooray SE. The effective treatment of severe repetitive behaviour with fluvoxamine in a 20 year old autistic female. Int Clin Psychopharmacol. 1995;10:201-203.
24. McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry. 1996;53:1001-1008.
25. Autism Speaks. Autism speaks announces results reported for the study of fluoxetine in autism (SOFIA): First industry-sponsored trial for the Autism Clinical Trials Network (ACTN) [press release]. New York: http://www.autismspeaks. org/about-us/press-releases/autism-speaks-announces-resultsreported- study-fluoxetine-autism-sofia; 2009; Feb 18.
26. Hollander E, Phillips A, Chaplin W, et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology. 2005;30:582-589
27. Damore J, Stine J, Brody L Medication-induced hypomania in Asperger's disorder. J Am Acad Child Adolesc Psychiatry. 1998;37:248-249.
28. Fatemi SH, Realmuto GM, Khan L, Thuras P. Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial. J Autism Dev Disord. 1998;28:303-307.
29. Cook EH, Jr, Rowlett R, Jaselskis C, Leventhal BL. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry. 1992;31:739-745.
30. Mehlinger R, Scheftner WA, Poznanski E. Fluoxetine and autism. J Am Acad Child Adolesc Psychiatry. 1990;29:985.
31. Koshes RJ. Use of fluoxetine for obsessive-compulsive behavior in adults with autism. Am J Psychiatry. 1997;154:578.
32. Ghaziuddin M, Tsai L, Ghaziuddin N. Fluoxetine in autism with depression. J Am Acad Child Adolesc Psychiatry. 1991;30:508-509.
33. Fontenelle LF, Mendlowicz MV, Bezerra de Menezes G, dos Santos Martins RR, Versiani M. Asperger Syndrome, obsessive-compulsive disorder, and major depression in a patient with 45,X/46,XY mosaicism. Psychopathology. 2004;37:105-109.
34. Hollander E, Soorya L, Chaplin W, et al. A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. Am J Psychiatry. 2012;169:292-299. Erratum: 2012;169:540.
35. Steingard RJ, Zimnitzky B, DeMaso DR, Bauman ML, Bucci JP. Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. J Child Adolesc Psychopharmacol. 1997;7:9-15.
36. Bhardwaj A, Agarwal V, Sitholey P. Asperger's disorder with co-morbid separation anxiety disorder: a case report. J Autism Dev Disord. 2005;35:135-136.
37. Hellings JA, Kelley LA, Gabrielli WF, Kilgore E, Shah P. Sertraline response in adults with mental retardation and autistic disorder. J Clin Psychiatry. 1996;57:333-336.
38. McDougle CJ, Brodkin ES, Naylor ST, Carlson DC, Cohen DJ, Price LH. Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation. J Clin Psychopharmacol. 1998;18:62-66.
39. Couturier JL, Nicolson R. A retrospective assessment of citalopram in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2002;12:243-248.
40. Namerow LB, Thomas P, Bostic JQ, Prince J, Monuteaux MC. Use of citalopram in pervasive developmental disorders. J Devel Behav Pediatr. 2003;24:104-108.
41. King BH, Hollander E, Sikich L, et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry. 2009;66:583-590.
42. Owley T, Walton L, Salt J, et al. An open-label trial of escitalopram in pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry. 2005;44:343-348.
43. Hollander E, Kaplan A, Cartwright C, Reichman D. Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report. J Child Neurol. 2000;15:132-135.
44. Carminati GG, Deriaz N, Bertschy G. Low-dose venlafaxine in three adolescents and young adults with autistic disorder improves self-injurious behavior and attention deficit/hyperactivity disorders (ADHD)-like symptoms. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:312-315.
45. Gedye A. Trazodone reduced aggressive and self-injurious movements in a mentally handicapped male patient with autism. J Clin Psychopharmacol. 1991;11:275-276.
46. Kem DL, Posey DJ, McDougle CJ. Priapism associated with trazodone in an adolescent with autism. J Am Acad Child Adolesc Psychiatry. 2002;41:758.
47. Posey DJ, Guenin KD, Kohn AE, Swiezy NB, McDougle CJ. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2001;11:267-277.
48. Nguyen M, Murphy T. Mirtazapine for excessive masturbation in an adolescent with autism. J Am Acad Child Adolesc Psychiatry. 2001;40:868-869.
49. Albertini G, Polito E, Sara M, Di Gennaro G, Onorati P. Compulsive masturbation in infantile autism treated by mirtazapine. Pediatr Neurol. 2006;34:417-418.
50. Coskun M, Mukaddes NM. Mirtazapine treatment in a subject with autistic disorder and fetishism. J Child Adolesc Psychopharmacol. 2008;18:206-209.
51. Coskun M, Karakoc S, Kircelli F, Mukaddes NM. Effectiveness of mirtazapine in the treatment of inappropriate sexual behaviors in individuals with autistic disorder. J Child Adolesc Psychopharmacol. 2009;19:203-206.
52. Campbell M, Anderson LT, Meier M, et al. A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Psychiatry. 1978;17:640-655.
53. Cohen IL, Campbell M, Posner D. A study of haloperidol in young autistic children: a within-subjects design using objective rating scales. Psychopharmacol Bull. 1980;16:63-65.
54. Anderson LT, Campbell M, Grega DM, Perry R, Small AM, Green WH. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry. 1984;141:1195-1202.
55. Locascio JJ, Malone RP, Small AM, et al. Factors related to haloperidol response and dyskinesias in autistic children. Psychopharmacol Bull. 1991;27:119-126.
56. Perry R, Campbell M, Adams P, et al. Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. J Am Acad Child Adolesc Psychiatry. 1989;28:87-92.
57. Campbell M, Armenteros JL, Malone RP, Adams PB, Eisenberg ZW, Overall JE. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry. 1997;36:835-843.
58. Faretra G, Dooher L, Dowling J. Comparison of haloperidol and fluphenazine in disturbed children. Am J Psychiatry. 1970;126:1670-1673.
59. Miral S, Gencer O, Inal-Emiroglu FN, Baykara B, Baykara A, Dirik E. Risperidone versus haloperidol in children and adolescents with AD : a randomized, controlled, double-blind trial. Eur Child Adolesc Psychiatry. 2008;17:1-8.
60. Gencer O, Emiroglu FN, Miral S, Baykara B, Baykara A, Dirik E. Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. An open label maintenance study. Eur Child Adolesc Psychiatry. 2008;17:217-225.
61. Malone RP, Cater J, Sheikh RM, Choudhury MS, Delaney MA. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry. 2001;40:887-894.
62. Ernst M, Gonzalez NM, Campbell M. Acute dystonic reaction with lowdose pimozide. J Am Acad Child Adolesc Psychiatry. 1993;32:640-642.
63. Naruse H, Nagahata M, Nakane Y, Shirahashi K, Takesada M, Yamazaki K. A multi-center double-blind trial of pimozide (Orap), haloperidol and placebo in children with behavioral disorders, using crossover design. Acta Paedopsychiatrica. 1982;48:173-184.
64. Zuddas A, Ledda MG, Fratta A, Muglia P, Cianchetti C. Clinical effects of clozapine on autistic disorder. Am J Psychiatry. 1996;153:738.
65. Chen NC, Bedair HS, McKay B, Bowers MB, Jr, Mazure C. Clozapine in the treatment of aggression in an adolescent with autistic disorder. J Clin Psychiatry. 2001;62:479-480.
66. Lambrey S, Falissard B, Martin-Barrero M, et al. Effectiveness of clozapine for the treatment of aggression in an adolescent with autistic disorder. J Child Adolesc Psychopharmacol. 2010;20:79-80.
67. Gobbi G, Pulvirenti L. Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behaviour. J Psychiatry Neurosci. 2001;26:340-341.
68. Beherec L, Lambrey S, Quilici G, Rosier A, Falissard B, Guillin O. Retrospective review of clozapine in the treatment of patients with autism spectrum disorder and severe disruptive behaviors. J Clin Psychopharmacol. 2011;31:341-344.
69. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347:314-321.
70. Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004;114:e634-e641.
71. Troost PW, Lahuis BE, Steenhuis MP, et al. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry. 2005;44:1137-1144.
72. Malone RP. Discontinuing risperidone results in relapse in children with autism spectrum disorders. Evid Based Ment Health. 2006;9:56.
73. Aman MG, Hollway JA, Leone S, et al. Effects of risperidone on cognitive- motor performance and motor movements in chronically medicated children. Res Dev Disabil. 2009;30:386-396.
74. Luby J, Mrakotsky C, Stalets MM, et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol. 2006;16:575-587.
75. Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol. 2006;21:450- 455.
76. Anderson GM, Scahill L, McCracken JT, et al. Effects of short- and longterm risperidone treatment on prolactin levels in children with autism. Biol Psychiatry. 2007;61:545-550.
77. Horrigan JP, Barnhill LJ. Risperidone and explosive aggressive autism. J Autism Dev Disord. 1997;27:313-323.
78. McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry. 1998;55:633-641.
79. Hellings JA, Zarcone JR, Reese RM, et al. A crossover study of risperidone in children, adolescents and adults with mental retardation. J Autism Dev Disord. 2006;36:401-411.
80. Hellings JA, Zarcone JR, Crandall K, Wallace D, Schroeder SR. Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J Child Adolesc Psychopharmacol. 2001;11:229-328.
81. Martin A, Scahill L, Anderson GM, et al. Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am J Psychiatry. 2004;161:1125-1127.
82. Stavrakaki C, Antochi R, Emery PC. Olanzapine in the treatment of pervasive developmental disorders: a case series analysis. J Psychiatry Neurosci. 2004;29:57-60.
83. Kemner C, Willemsen-Swinkels SH, de Jonge M, Tuynman-Qua H, van Engeland H. Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol. 2002;22:455-460.
84. Fido A, Al-Saad S. Olanzapine in the treatment of behavioral problems associated with autism: an open-label trial in Kuwait. Med Princ Pract. 2008;17:415-418.
85. Potenza MN, Holmes JP, Kanes SJ, McDougle CJ. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol. 1999;19:37-44.
86. Milin R, Simeon JG, Batth S, Thatte S, Dare GJ, Walker S. An open trial of olanzapine in children and adolescents with Asperger Disorder. J Clin Psychopharmacol. 2006;26:90-92.
87. Hollander E, Wasserman S, Swanson EN, et al. A double-blind placebocontrolled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol. 2006;16:541-548.
88. Corson AH, Barkenbus JE, Posey DJ, Stigler KA, McDougle CJ. A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. J Clin Psychiatry. 2004;65:1531-1536.
89. Hardan AY, Jou RJ, Handen BL. Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders. J Autism Dev Disord. 2005;35:387-391.
90. Martin A, Koenig K, Scahill L, Bregman J. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol. 1999;9:99-107.
91. Findling RL, McNamara NK, Gracious BL, et al. Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol. 2004;14:287- 294.
92. Goforth HW, Rao MS. Improvement in behaviour and attention in an autistic patient treated with ziprasidone. Aust N Z J Psychiatry. 2003;37:775-776.
93. Duggal HS. Ziprasidone for maladaptive behavior and attentiondeficit/ hyperactivity disorder symptoms in autistic disorder. J Child Adolesc Psychopharmacol. 2007;17:261-263.
94. Cohen SA, Fitzgerald BJ, Khan SR, Khan A. The effect of a switch to ziprasidone in an adult population with autistic disorder: chart review of naturalistic, open-label treatment. J Clin Psychiatry. 2004;65:110-113.
95. McDougle CJ, Kem DL, Posey DJ. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry. 2002;41:921-927.
96. Malone RP, Delaney MA, Hyman SB, Cater JR. Ziprasidone in adolescents with autism: an open-label pilot study. J Child Adolesc Psychopharmacol. 2007;17:779-790.
97. Marcus RN, Owen R, Kamen L, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009;48:1110-1119.
98. Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009;124:1533-1540.
99. Marcus RN, Owen R, Manos G, et al. Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study. J Clin Psychiatry. 2011;72:1270-1276.
100. Marcus RN, Owen R, Manos G, et al. Aripiprazole in the treatment of irritability in pediatric patients (aged 6-17 years) with autistic disorder: results from a 52-week, open-label study. J Child Adolesc Psychopharmacol. 2011;21:229-236.
101. Stigler KA, Posey DJ, McDougle CJ. Case series: piripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2004;14:463-471.
102. Stigler KA, Diener JT, Kohn AE, et al. Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14- week, prospective, open-label study. J Child Adolesc Psychopharmacol. 2009;19:265-274.
103. Valicenti-McDermott MR, Demb H. Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. J Child Adolesc Psychopharmacol. 2006;16:549-560.
104. Shastri M, Alla L, Sabaratnam M. Aripiprazole use in individuals with intellectual disability and psychotic or behavioural disorders: a case series. J Psychopharmacol. 2006;20:863-867.
105. Shepherd J, Garza VM, De Leon OA. Waxing-and-waning catatonia after intermittent exposure to aripiprazole in a case of autism and bipolar disorder. J Clin Psychopharmacol. 2009;29:503-504.
106. Stigler KA, Erickson CA, Mullett JE, Posey DJ, McDougle CJ. Paliperidone for irritability in autistic disorder. J Child Adolesc Psychopharmacol. 2010;20:75-78.
107. Kowalski JL, Wink LK, Blankenship K, et al. Paliperidone palmitate in a child with autistic disorder. J Child Adolesc Psychopharmacol. 2011;21:491-493.
108. Stigler KA, Mullett JE, Erickson CA, Posey DJ, McDougle CJ. Paliperidone for irritability in adolescents and young adults with autistic disorder. Psychopharmacology (Berl). 2012;223:237-245.
109. Greenhill L, Beyer DH, Finkleson J, et al. Guidelines and algorithms for the use of methylphenidate in children with Attention-Deficit/ Hyperactivity Disorder. J Attent Disord. 2002;6(suppl 1):S89-S100.
110. Greenhill LL, Pliszka S, Dulcan MK, et al. Summary of the practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2001;40:1352-1355.
111. Schmidt K. The effect of stimulant medication in childhood-onset pervasive developmental disorder--a case report. J Devel Behav Pediatr. 1982;3:244-246.
112. Birmaher B, Quintana H, Greenhill LL. Methylphenidate treatment of hyperactive autistic children. J Am Acad Child Adolesc Psychiatry. 1988;27:248-251.
113. Strayhorn JM, Jr., Rapp N, Donina W, Strain PS. Randomized trial of methylphenidate for an autistic child. J Am Acad Child Adolesc Psychiatry. 1988;27:244-247.
114. Quintana H, Birmaher B, Stedge D, et al. Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord. 1995;25:283-294.
115. Handen BL, Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord. 2000;30:245-255.
116. Research Units on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry. 2005;62:1266-1274.
117. Santosh PJ, Baird G, Pityaratstian N, Tavare E, Gringras P. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study. Child: Care Health Dev. 2006;32:575-583.
118. Posey DJ, Aman MG, McCracken JT, et al. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. Biol Psychiatry. 2007;61:538-544.
119. Nickels K, Katusic SK, Colligan RC, Weaver AL, Voigt RG, Barbaresi WJ. Stimulant medication treatment of target behaviors in children with autism: a population-based study. J Devel Behav Pediatr. 2008;29:75-81.
120. Ghuman JK, Aman MG, Lecavalier L, et al. Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders. J Child Adolesc Psychopharmacol. 2009;19:329-339.
121. Jahromi LB, Kasari CL, McCracken JT, Lee LS, Aman MG, McDougle CJ, et al. Positive effects of methylphenidate on social communication and selfregulation in children with pervasive developmental disorders and hyperactivity. J Autism Dev Disord. 2009;39:395-404.
122. Stigler KA, Desmond LA, Posey DJ, Wiegand RE, McDougle CJ. A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2004;14:49-56.
123. Roy M, Dillo W, Bessling S, Emrich HM, Ohlmeier MD. Effective methylphenidate treatment of an adult Aspergers Syndrome and a comorbid ADHD: a clinical investigation with fMRI. J Attent Disord. 2009;12:381-385.
124. Jou RJ, Handen BL, Hardan AY. Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2005;15:325-330.
125. Posey DJ, Wiegand RE, Wilkerson J, Maynard M, Stigler KA, McDougle CJ. Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006;16:599-610.
126. Troost PW, Steenhuis MP, Tuynman-Qua HG, et al. Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study. J Child Adolesc Psychopharmacol. 2006;16:611-619.
127. Arnold LE, Aman MG, Cook AM, et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry. 2006;45:1196-1205.
128. Niederhofer H, Damodharan SK, Joji R, Corfield A. Atomoxetine treating patients with Autistic disorder. Autism. 2006;10:647-649.
129. Ming X, Gordon E, Kang N, Wagner GC. Use of clonidine in children with autism spectrum disorders. Brain Dev. 2008;30:454-460.
130. Jaselskis CA, Cook EH, Jr., Fletcher KE, Leventhal BL. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol. 1992;12:322-327.
131. Fankhauser MP, Karumanchi VC, German ML, Yates A, Karumanchi SD. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry. 1992;53:77-82.
132. Koshes RJ, Rock NL. Use of clonidine for behavioral control in an adult patient with autism. Am J Psychiatry. 1994;151:1714.
133. Posey DJ, Puntney JI, Sasher TM, Kem DL, McDougle CJ. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol. 2004;14:233-241.
134. Scahill L, Aman MG, McDougle CJ, et al. A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006;16:589-598.
135. Handen BL, Sahl R, Hardan AY. Guanfacine in children with autism and/or intellectual disabilities. J Devel Behav Pediatr. 2008;29:303-308.
136. Blankenship K, Erickson CA, Stigler KA, Posey DJ, McDougle CJ. Guanfacine extended release in two patients with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2011;21:287-290.
137. Posey DJ, Kem DL, Swiezy NB, Sweeten TL, Wiegand RE, McDougle CJ. A pilot study of D-cycloserine in subjects with autistic disorder. Am J Psychiatry. 2004;161:2115-2117.
138. Bernhardt EB, Walsh KH, Posey DJ, McDougle CJ. Memantine for comorbid obsessive-compulsive disorder and Asperger disorder suggests a link in glutamatergic dysregulation. J Clin Psychopharmacol. 2011;31:673- 675.
139. Erickson CA, Chambers JE. Memantine for disruptive behavior in autistic disorder. J Clin Psychiatry. 2006;67:1000.
140. Erickson CA, Posey DJ, Stigler KA, Mullett J, Katschke AR, McDougle CJ. A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl). 2007;191:141-147.
141. Owley T, Salt J, Guter S, et al. A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006;16:517-524.
142. Chez MG, Burton Q, Dowling T, Chang M, Khanna P, Kramer C. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol. 2007;22:574-579.